We are live on ! Find out more
QNRX

Quoin Pharmaceuticals

6 hedge funds and large institutions have $272K invested in Quoin Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.82% more ownership

Funds ownership: 1.69% → 2.51% (+0.82%)

15% less capital invested

Capital invested by funds: $321K → $272K (-$49K)

25% less funds holding

Funds holding: 8 → 6 (-2)

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

Holders
6
Holders Change
-2
Holders Change %
-25%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
–
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

QNRX Hedge Fund Activity: Q3 2022 in Review

6 of the 5,829 institutional investors tracked by Wall St. Rank reported a position in Quoin Pharmaceuticals (QNRX) for Q3 2022, worth a combined $272K — down 15% from $321K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of QNRX and 4 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 2 added.

The largest buyer was Ground Swell Capital, opening a new position worth an estimated $179K. The largest seller was Ameriprise, exiting entirely with an estimated $256K sold.

  • 6 institutional investors held Quoin Pharmaceuticals (QNRX) as of Q3 2022, down from 8 in Q2 2022.
  • Funds reported $272K of Quoin Pharmaceuticals stock for Q3 2022, down 15% quarter-over-quarter.
  • 4 funds opened new Quoin Pharmaceuticals positions in Q3 2022 and 6 closed out, a net change of -2 holders.
  • The largest Quoin Pharmaceuticals buyer in Q3 2022 was Ground Swell Capital, an estimated $179K added.
  • The largest Quoin Pharmaceuticals seller in Q3 2022 was Ameriprise, an estimated $256K sold.

Based on aggregated 13F filings for Q3 2022.